SE
63
5
PEP
41
-6
NEM
50
2
PCG
56
-2
IP
54
-2
BA
65
2
CFG
48
-2
NOV
43
4
WEC
43
-2
XRAY
50
4
NDAQ
56
4
GD
39
-2
VMC
51
3
HBAN
56
2
AMP
54
2
GME
57
5
ROST
66
-2
BAX
29
-4
DNB
58
-2
DAL
64
2
SE
63
5
PEP
41
-6
NEM
50
2
PCG
56
-2
IP
54
-2
BA
65
2
CFG
48
-2
NOV
43
4
WEC
43
-2
XRAY
50
4
NDAQ
56
4
GD
39
-2
VMC
51
3
HBAN
56
2
AMP
54
2
GME
57
5
ROST
66
-2
BAX
29
-4
DNB
58
-2
DAL
64
2
Financhill
Back

Knight Therapeutics 10K Form

Sell
16

GUD.TO
Knight Therapeutics

Last Price:
5.28
Seasonality Move:
0.47%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive GUD.TO News And Ratings

See the #1 stock for the next 7 days that we like better than GUD.TO

GUD.TO Financial Statistics

Sales & Book Value

Annual Sales: $328.2M
Cash Flow: $3.03M
Price / Cash Flow: 26.06
Annual Sales: $7.66
Price / Book: 0.69

Profitability

EPS (TTM): -0.28920
Net Income (TTM): $-30.73M
Gross Margin: $152.65M
Return on Equity: -3.98%
Return on Assets: -3.18%

Knight Therapeutics Earnings Forecast

Key Knight Therapeutics Financial Ratios

  • The Gross Profit Margin over the past 10 years for GUD.TO is 46.51%.
  • The Selling, General & Administrative Expenses for GUD.TO have been equal to 25.50% of Gross Profit Margin.
  • The Research & Development expenses have been 5.35% of Revenue.
  • The Interest Expense is -74.18% of Operating Income.
  • The Net Earning history of GUD.TO is -5.13% of Total Revenues.
  • Per Share Earnings over the last 10 years have been positive in 3 years.

Knight Therapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: TSX
Industry: Pharmaceuticals
Sector: Health Care
Current Symbol: GUD.TO
Website: gud-knight.com

Debt

Debt-to-Equity Ratio: 0.07
Current Ratio: 3.36
Quick Ratio: 2.33

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 264

GUD.TO Technical Analysis vs Fundamental Analysis

Sell
16
Knight Therapeutics (GUD.TO) is a Sell

Is Knight Therapeutics a Buy or a Sell?